Pembrolizumab for the treatment of non-small-cell lung cancer
Antibodies, Monoclonal, Humanized
Carcinoma, Non-Small-Cell Lung
Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer. PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolizumab. (Funded by Merck; KEYNOTE-001 ClinicalTrials.gov number, NCT01295827.).